Phased implementation of pathogen-reduced platelets in a health system facilitates increased manufacturing at the blood center.

Phased implementation is a practical and ethical way to introduce PR PLTs in a health system and facilitates scalability at the blood center. Widespread availability of PR products may require collective action and can be increased by optimization strategies during manufacturing.